| P2093 | author name string | Kanwal Saba | |
| | Mulazim Hussain Bukhari | |
| | Sadaf Farzand | |
| | Tahir Siddique | |
| P2860 | cites work | Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial | Q27824810 |
| | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 |
| | HER 2/neu protein expression in colorectal cancer | Q33242725 |
| | Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry | Q33398141 |
| | Biologic and therapeutic role of HER2 in cancer | Q34267775 |
| | The HER-2/neu oncogene in tumors of the gastrointestinal tract | Q34311106 |
| | Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma | Q34756800 |
| | HER-2/neu and topoisomerase IIalpha--simultaneous drug targets in cancer | Q35181105 |
| | Comparison of the 6th and 7th Editions of the UICC-AJCC TNM Classification for Esophageal Cancer | Q36052315 |
| | c-erbB-2 is not a major factor in the development of colorectal cancer | Q36644043 |
| | Assessment of a HER2 scoring system for gastric cancer: results from a validation study | Q37142266 |
| | HER2-positive gastric cancer | Q37468290 |
| | Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial | Q38447818 |
| | HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial | Q38455547 |
| | HER-2/neu amplification is an independent prognostic factor in gastric cancer. | Q40303656 |
| | Clinical utility of type 1 growth factor receptor expression in colon cancer | Q43509732 |
| | All signaling is local? | Q44111116 |
| | Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu | Q45174616 |
| | Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome | Q47231231 |
| | HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder | Q47794879 |
| | HER-2/neu and p53 in osteosarcoma: an immunohistochemical and fluorescence in situ hybridization analysis | Q47802235 |
| | HER 2/neu expression and gene amplification in colon cancer | Q47887121 |
| | [Clinical study of the predictors to neoadjuvant chemotherapy in patients with advanced gastric cancer]. | Q54441051 |
| | The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer | Q73212054 |
| | HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors | Q75209089 |
| | HER 2/neu protein expression in gastric cancer is associated with poor survival | Q83811754 |
| | [Correlation between the expression of HER-2/neu, nm23 protein and local invasion and lymph node metastasis of human LSCC] | Q83890602 |
| | A prospective comparison of totally minimally invasive versus open Ivor Lewis esophagectomy | Q86528965 |
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | adenocarcinoma | Q356033 |
| | overexpression | Q61643320 |
| P304 | page(s) | 5889-5896 | |
| P577 | publication date | 2014-05-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Frequency of HER2/neu overexpression in adenocarcinoma of the gastrointestinal system | |
| P478 | volume | 20 | |